APA (7th ed.) Citation

Mezquita, L., Xenophontos, E., Pretzenbaher, Y., Sureda, C., Nadal, E., Al-Rabi, K., . . . Dingemans, A. (2023). 1509TiP The 1825-EORTC, ALKALINE: Activity of lorlatinib based on ALK resistance mutations on blood in ALK positive NSCLC patients previously treated with second generation ALK inhibitor. Annals of Oncology, 34, S849. https://doi.org/10.1016/j.annonc.2023.09.2540

Chicago Style (17th ed.) Citation

Mezquita, L., et al. "1509TiP The 1825-EORTC, ALKALINE: Activity of Lorlatinib Based on ALK Resistance Mutations on Blood in ALK Positive NSCLC Patients Previously Treated with Second Generation ALK Inhibitor." Annals of Oncology 34 (2023): S849. https://doi.org/10.1016/j.annonc.2023.09.2540.

MLA (9th ed.) Citation

Mezquita, L., et al. "1509TiP The 1825-EORTC, ALKALINE: Activity of Lorlatinib Based on ALK Resistance Mutations on Blood in ALK Positive NSCLC Patients Previously Treated with Second Generation ALK Inhibitor." Annals of Oncology, vol. 34, 2023, p. S849, https://doi.org/10.1016/j.annonc.2023.09.2540.